Европейски съюз - български - EMA (European Medicines Agency)

merck europe b.v. - Кладрибин - Множествена склероза - Имуносупресори - Лечение на възрастни пациенти с много активна рецидивираща множествена склероза (МС), както е определено чрез клинични или образни признаци.

България - български - Изпълнителна агенция по лекарствата

sanofi pasteur s.a. - Хепатит А, инактивированная, цял вирус - 0,5 ml suspension for injection

България - български - Изпълнителна агенция по лекарствата

sanofi pasteur s.a. - Хепатит А, инактивированная, цял вирус - 0,5 ml suspension for injection

България - български - Изпълнителна агенция по лекарствата

glaxosmithkline biologicals - Хепатит В пречистен антиген - 10 micrograms/0,5 ml suspension for injection

България - български - Изпълнителна агенция по лекарствата

glaxosmithkline biologicals - Хепатит В пречистен антиген - 20 micrograms/1 ml suspension for injection

България - български - Изпълнителна агенция по лекарствата

glaxosmithkline biologicals - Хепатит А, инактивированная, цял вирус - suspension for injection ( junior monodose)

България - български - Изпълнителна агенция по лекарствата

glaxosmithkline biologicals - Хепатит А, инактивированная, цял вирус - suspension for injection ( adult dose)

Европейски съюз - български - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon алфа-2b - Истинска Полицитемия - Иммуностимуляторы, - besremi включен като монотерапии при възрастни за лечение на полицитемия вера, без симптоматично спленомегалии.

Европейски съюз - български - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - Отхвърляне на присадката - Имуносупресори - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Европейски съюз - български - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - Имуносупресори - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.